Dexcel Pharma Executive and Leadership Team

Uri Oren, the Co-Chief Executive Officer at Dexcel Pharma, directs the strategic expansion of the company into diverse international markets. Overseeing the commercialization of branded prescription drugs, the Co-Chief Executive Officer ensures that the organization maintains a competitive edge across the U.K., Germany, and Austria. This leadership role involves constant collaboration with the Board to refine the long-term vision for oral solid dosage forms. By optimizing distribution partnerships, Uri Oren directly impacts the global reach of the product portfolio. The Co-Chief Executive Officer monitors market trends to identify new opportunities for growth within the pharmaceutical sector. Through precise management of corporate resources, Oren secures the stability of the enterprise. This executive focus remains on scaling production capabilities to meet the rising demand for high-quality generics while upholding the reputation of the firm as a leader in the pharmaceutical industry.

Dan Oren, the President & Chief Executive Officer at Dexcel Pharma, architects the overarching corporate mission and drives the development of value-added pharmaceutical solutions. Managing the executive team, the President & Chief Executive Officer aligns internal manufacturing processes with the complex regulatory requirements of the U.S. and other major markets. This leadership role requires balancing innovation in drug development with the operational demands of a large-scale private entity. By fostering a culture of excellence, Dan Oren ensures that the company remains at the forefront of the industry. The President & Chief Executive Officer oversees the integration of new product lines into the existing portfolio of over 85 products. Through strategic oversight, Oren maintains the financial health and market position of the organization. This executive leadership supports the continuous improvement of manufacturing standards to ensure patient safety and product efficacy across all global regions.

Ilan Oren, the Co-Chief Executive Officer at Dexcel Pharma, manages the operational infrastructure and supply chain logistics necessary for global distribution. Coordinating with international subsidiaries, the Co-Chief Executive Officer ensures that the manufacturing of oral solid dosage forms meets the highest quality benchmarks. This leadership role involves streamlining production workflows to increase efficiency and reduce time-to-market for new OTC products. By implementing advanced manufacturing technologies, Ilan Oren directly enhances the output capacity of the company. The Co-Chief Executive Officer evaluates performance metrics to optimize resource allocation across the various production facilities. Through rigorous oversight of the supply chain, Oren guarantees the consistent availability of essential medications. This executive focus remains on maintaining the operational integrity of the firm while supporting the broader strategic goals of the organization in the competitive pharmaceutical landscape.

Yaron Erez, the Chief Financial Officer & Vice President at Dexcel Pharma, manages the financial planning, reporting, and capital allocation strategies for the company. Overseeing the fiscal health of the organization, the Chief Financial Officer & Vice President ensures that investments in manufacturing and R&D align with the long-term growth objectives. This leadership role involves monitoring the financial performance of international subsidiaries to maintain profitability across diverse markets. By optimizing the capital structure, Yaron Erez supports the expansion of the product portfolio. The Chief Financial Officer & Vice President collaborates with other executives to assess the financial viability of new market entries and product launches. Through disciplined fiscal management, Erez secures the resources required for sustained development. This executive leadership ensures that the company maintains a strong balance sheet while navigating the economic complexities of the global pharmaceutical industry.

Ziv Teresh, the Chief Operating Officer & Vice President at Dexcel Pharma, directs the day-to-day manufacturing operations and facility management. Overseeing the production of oral solid dosage forms, the Chief Operating Officer & Vice President ensures that all processes adhere to strict regulatory standards and internal quality protocols. This leadership role involves optimizing the manufacturing floor to maximize output and minimize waste. By coordinating with the supply chain team, Ziv Teresh ensures the timely delivery of products to distribution partners worldwide. The Chief Operating Officer & Vice President monitors operational KPIs to identify areas for continuous improvement. Through the implementation of lean manufacturing principles, Teresh enhances the overall productivity of the firm. This executive leadership supports the company's commitment to delivering high-quality pharmaceutical products by maintaining a safe, efficient, and compliant production environment across all manufacturing sites.

Miri Peleg, the Vice President, Chief Information Officer at Dexcel Pharma, directs the digital transformation and information security strategies for the entire organization. Overseeing the implementation of enterprise-wide software solutions, the Vice President, Chief Information Officer ensures that data integrity remains a priority during the manufacturing and distribution of pharmaceutical products. This leadership role involves modernizing the IT infrastructure to support the complex needs of a global pharmaceutical company. By leveraging data analytics, Miri Peleg provides actionable insights that drive decision-making across the C-suite. The Vice President, Chief Information Officer manages the cybersecurity posture to protect sensitive research and development information. Through the deployment of scalable technology, Peleg supports the operational efficiency of the firm. This executive leadership ensures that the company maintains a robust digital foundation to facilitate growth and innovation in the highly regulated pharmaceutical market.

Esther Hagai, the Chief Medical Officer at Dexcel Pharma, directs the clinical development and medical affairs strategy for the company. Overseeing the scientific validation of new drugs, the Chief Medical Officer ensures that all products meet the highest standards of safety and efficacy before reaching the market. This leadership role involves managing clinical trials and engaging with regulatory bodies to secure necessary approvals for branded prescription drugs. By providing medical expertise, Esther Hagai guides the R&D team in developing innovative solutions that address unmet patient needs. The Chief Medical Officer monitors the safety profile of the existing product portfolio to ensure ongoing compliance with global health regulations. Through rigorous scientific oversight, Hagai maintains the medical integrity of the firm. This executive leadership supports the company's mission by ensuring that every product contributes positively to patient health outcomes in the international pharmaceutical market.